Dengue Vaccine Controversy In Philippines Could ‘Erode Public Confidence’ In Country’s Health Endeavors

SciDev.Net: Dengue vaccination: when being the first is a bad idea
Crispin Maslog, founding member and current chair of the Board of the Asian Media Information and Communication Centre

“When the Philippines launched its dengue vaccination program on 4 April 2016, using Sanofi Pasteur’s newly approved ‘Dengvaxia,’ there was great fanfare and optimism. This week, the Public Attorney’s Office has filed a lawsuit against the company, seeking compensation for the death of a 10-year-old girl it says has died as a result of the vaccine. It follows an investigation of the halted program by the Philippine Senate. … [A]s Philippine scientists and politicians fight over the failure of Asia’s first mass dengue vaccination program, the biggest casualty may be people’s trust and confidence in vaccination and other government-led public health programs as an effective way to fight diseases. … The Philippine government could have been more conservative in adopting the new vaccine, especially in this case, since it involves children. … In hindsight, it looks like Filipino children became unwitting guinea pigs in the rush to roll out a new dengue vaccine, with the scientific and health community’s reputation taking a hit as well” (2/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.